Avaí Bio–Austrianova’s longevity protein program enters production
Lithuania-based Avaí Bio and Singapore's Austrianova have begun GMP production of a Master Cell Bank of genetically modified cells that overexpress α-Klotho for use in Austrianova's Cell-in-a-Box encapsulated cell therapy. The MCB step signals manufacturing and regulatory preparation for continuous α-Klotho delivery—linked in JAMA Neurology to cognitive resilience—while safety validation and human trials still lie ahead.
Why it mattersGMP Master Cell Bank for α‑Klotho signals manufacturing readiness; investors should adjust clinical and capital timelines.
People Mentioned
Kyle Umipig